Clinical Trial

PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months. The purpose of this study is to evaluate the immunogenicity and safety of the 24-valent pneumococcal polysaccharide conjugate vaccine.
Protocol Amendment History 4 changes
critical Trial completed 2026-07-28
notable Primary completion moved earlier: 2027-07 -> 2026-04-14 2026-07-28
minor Completion moved earlier: 2027-08 -> 2026-04-14 2026-07-28
notable Sponsor changed: Shanghai Reinovax Biologics Co.,LTD -> Reinovax Biologics Co., LTD 2026-07-26
Trial Details
NCT Number NCT07333352
Lead Sponsor Reinovax Biologics Co., LTD
Conditions Pneumococcal Infectious Disease
Enrollment 480 participants
Start Date 2025-09-11
Primary Completion 2026-04-14 (estimated)
Study Completion 2026-04-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-27